Glycosylation as a strategy to improve antibody-based therapeutics

  title={Glycosylation as a strategy to improve antibody-based therapeutics},
  author={Royston Jefferis},
  journal={Nature Reviews Drug Discovery},
To date, more than 20 recombinant immunoglobulin G (IgG) antibody therapeutics are licensed for the treatment of various diseases. The mechanism of action of recombinant monoclonal antibodies (rMAbs) has been extensively investigated and several distinct pathways have been defined; selective activation of specific pathways may optimize clinical outcomes for different diseases, such as cancer and chronic inflammation. Human IgG is a glycoprotein with oligosaccharides attached at a single site… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 247 extracted citations


Publications referenced by this paper.
Showing 1-10 of 76 references

Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content

R Keck
Biologicals 36, • 2008

Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function

Q Zhou
Biotechnol. Bioeng • 2008

Similar Papers

Loading similar papers…